Trial Profile
A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Aug 2018
Price :
$35
*
At a glance
- Drugs MCS 2 (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Acronyms MCS_LUTS
- Sponsors Health Ever Bio-Tech
- 27 Nov 2015 According to a Health Ever Bio Tech media release, it the only Taiwanese biotechnology company to receive US FDA Botanical New Drug IND approval for conducting Phase III clinical trials.
- 27 Nov 2015 New trial record